Patent application number | Description | Published |
20090099094 | Use of Somatostatin Agonists to Treat Medullary Thyroid Carcinoma - The present invention is directed to a method of determining a treatment to effectively combat medullary thyroid carcinoma and to suppress the secretion of calcitonin from medullary thyroid carcinoma cells. The present invention also provides a method of suppressing the secretion of calcitonin from medullary thyroid carcinoma cells and decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more somatostatin agonists. | 04-16-2009 |
20090156483 | Analogs of Ghrelin - The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: | 06-18-2009 |
20090163416 | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment - A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib | 06-25-2009 |
20100113367 | PEPTIDE-CYTOTOXIC CONJUGATES - The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions. | 05-06-2010 |
20100311647 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance. | 12-09-2010 |
20110160133 | METHOD FOR INHIBITING INFLAMMATION AND PRE-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE - The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin. | 06-30-2011 |
20110183416 | Method of modulating the proliferation of medullary thyroid carcinoma cells - The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A preferred selective somatostatin receptor type-2 (SSTR-2) agonist cyclo[Tic-Tyr-D-Trp-Lys-Abu-Phe] is also disclosed. | 07-28-2011 |
20120129767 | USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT - A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib | 05-24-2012 |
20120135923 | Use of Melanocortins to Treat Dyslipidemia - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease. | 05-31-2012 |
20130331324 | USE OF MELANOCORTINS TO TREAT DYSLIPIDEMIA - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of dyslipidemia and associated complications such as alcoholic and non-alcoholic fatty liver disease. | 12-12-2013 |